548 related articles for article (PubMed ID: 20134195)
1. Disease-modifying immunotherapy for the management of autoimmune diabetes.
Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
[TBL] [Abstract][Full Text] [Related]
2. New prospects for immunotherapy at diagnosis of type 1 diabetes.
Pozzilli P; Leslie RD
Diabetes Metab Res Rev; 2009 May; 25(4):299-301. PubMed ID: 19405079
[TBL] [Abstract][Full Text] [Related]
3. Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes?
Li DS; Warnock GL; Tu HJ; Ao Z; He Z; Lu H; Dai LJ
Life Sci; 2009 Oct; 85(15-16):549-56. PubMed ID: 19747492
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for the prevention and treatment of type 1 diabetes.
Goudy KS; Tisch R
Int Rev Immunol; 2005; 24(5-6):307-26. PubMed ID: 16318984
[TBL] [Abstract][Full Text] [Related]
5. Dysrulation of T cell peripheral tolerance in type 1 diabetes.
Tisch R; Wang B
Adv Immunol; 2008; 100():125-49. PubMed ID: 19111165
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation and regeneration of islet Beta cells by cytokines in autoimmune type 1 diabetes.
Singh B; Nikoopour E; Huszarik K; Elliott JF; Jevnikar AM
J Interferon Cytokine Res; 2011 Oct; 31(10):711-9. PubMed ID: 21851268
[TBL] [Abstract][Full Text] [Related]
7. Plasmacytoid dendritic cells in autoimmune diabetes - potential tools for immunotherapy.
Nikolic T; Welzen-Coppens JM; Leenen PJ; Drexhage HA; Versnel MA
Immunobiology; 2009; 214(9-10):791-9. PubMed ID: 19628297
[TBL] [Abstract][Full Text] [Related]
8. Thymus and type 1 diabetes: an update.
Geenen V
Diabetes Res Clin Pract; 2012 Oct; 98(1):26-32. PubMed ID: 22717497
[TBL] [Abstract][Full Text] [Related]
9. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation.
Khadra A; Santamaria P; Edelstein-Keshet L
J Theor Biol; 2009 Jan; 256(1):126-41. PubMed ID: 18950644
[TBL] [Abstract][Full Text] [Related]
10. T-lymphocyte recognition of beta cells in type 1 diabetes: clinical perspectives.
Boitard C
Diabetes Metab; 2013 Dec; 39(6):459-66. PubMed ID: 24139825
[TBL] [Abstract][Full Text] [Related]
11. Of mice and men: use of animal models to identify possible interventions for the prevention of autoimmune type 1 diabetes in humans.
Serreze DV; Chen YG
Trends Immunol; 2005 Nov; 26(11):603-7. PubMed ID: 16140038
[TBL] [Abstract][Full Text] [Related]
12. Rehabilitation of adaptive immunity and regeneration of beta cells.
Pasquali L; Fan Y; Trucco M; Ringquist S
Trends Biotechnol; 2006 Nov; 24(11):516-22. PubMed ID: 16963140
[TBL] [Abstract][Full Text] [Related]
13. Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage.
Waldron-Lynch F; Herold KC
Endocrinol Metab Clin North Am; 2009 Jun; 38(2):303-17, viii. PubMed ID: 19328413
[TBL] [Abstract][Full Text] [Related]
14. 'Sensing' autoimmunity in type 1 diabetes.
Tsui H; Razavi R; Chan Y; Yantha J; Dosch HM
Trends Mol Med; 2007 Oct; 13(10):405-13. PubMed ID: 17900987
[TBL] [Abstract][Full Text] [Related]
15. Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes.
Jiang GX; Cui YF; Zhong XY; Tai S; Liu W; Wang ZD; Shi YG
Arch Med Res; 2009 Jul; 40(5):424-6. PubMed ID: 19766909
[TBL] [Abstract][Full Text] [Related]
16. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice.
Pop SM; Wong CP; He Q; Wang Y; Wallet MA; Goudy KS; Tisch R
Diabetes; 2007 May; 56(5):1395-402. PubMed ID: 17317763
[TBL] [Abstract][Full Text] [Related]
17. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
18. CD8+ T cells in type 1 diabetes.
Tsai S; Shameli A; Santamaria P
Adv Immunol; 2008; 100():79-124. PubMed ID: 19111164
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1D.
Boettler T; von Herrath M
Int Immunopharmacol; 2010 Dec; 10(12):1491-5. PubMed ID: 20667487
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the age-at-onset heterogeneity in type 1 diabetes through mathematical modeling.
Wang X; He Z; Ghosh S
Math Biosci; 2006 Sep; 203(1):79-99. PubMed ID: 16723139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
